Antimetabolitlerin Klinik Kullanımları ve Yan Etki Yönetimi
Özet
Antimetabolitler, normal hücresel metabolitlerin yapısını taklit ederek DNA sentezini ve hücre çoğalmasını bozan sitotoksik ajanlardır. Bu tedavi yaklaşımı, gastrointestinal sistem, meme, akciğer ve hematolojik maligniteler başta olmak üzere geniş bir kanser yelpazesinde temel omurgayı oluşturur. Ancak, terapötik aralıklarının dar olması ve germ-line farmakogenomik polimorfizmler (DPD, TPMT vb.) nedeniyle bireyler arasında ciddi toksisite değişkenliği görülür. Antifolatlar (metotreksat, pemetrekset), floropirimidinler (5-FU, kapesitabin, TAS-102) ve pürin/pirimidin analogları (sitarabin, gemsitabin, fludarabin, kladribin) bu grubun önemli üyeleridir. Tedavi süreçlerinde doz sınırlayıcı en belirgin yan etki miyelosupresyon ve mukozit gibi gastrointestinal toksisitedir. Ayrıca, kapesitabin ile el-ayak sendromu, 5-FU ile kardiyotoksisite ve sitarabin ile yüksek dozlarda nörolojik komplikasyonlar gözlenebilir. Yan etki yönetiminde agresif hidrasyon, idrar alkalinizasyonu, folik asit/B12 takviyesi, steroid premedikasyonu ve gerekli durumlarda doz azaltımı veya tedaviye ara verilmesi kritik önem taşır. Hastaların tam kan sayımı, böbrek ve karaciğer fonksiyonları ile ilaç etkileşimleri açısından yakından takibi başarının anahtarıdır.
Antimetabolites are cytotoxic agents that disrupt DNA synthesis and cell proliferation by mimicking the structure of essential metabolites. This therapeutic strategy forms the backbone of treatment for a wide spectrum of malignancies, particularly gastrointestinal, breast, lung, and hematological cancers. However, due to their narrow therapeutic windows and germ-line pharmacogenomic polymorphisms (such as DPD and TPMT), significant inter-individual variability in toxicity occurs. Antifolates (methotrexate, pemetrexed), fluoropyrimidines (5-FU, capecitabine, TAS-102), and purine/pyrimidine analogs (cytarabine, gemcitabine, fludarabine, cladribine) represent key members of this class. The most prominent dose-limiting toxicities across these agents are myelosuppression and gastrointestinal side effects like mucositis. Additionally, hand-foot syndrome with capecitabine, cardiotoxicity with 5-FU, and neurological complications with high-dose cytarabine can be observed. Effective management relies heavily on aggressive hydration, urinary alkalinization, folic acid/vitamin B12 supplementation, steroid premedication, and temporary treatment interruption or dose reductions when necessary. Rigorous monitoring of complete blood counts, renal and hepatic functions, and potential drug interactions remains paramount for clinical success.
Referanslar
Howard, S. C., McCormick, J., Pui, C. H., Buddington, R. K., & Harvey, R. D. (2016). Preventing and managing toxicities of high-dose methotrexate. The oncologist, 21(12), 1471-1482.
Scagliotti, G. V., Shin, D. M., Kindler, H. L., Vasconcelles, M. J., Keppler, U., Manegold, C., ... & Rusthoven, J. J. (2003). Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. Journal of clinical oncology, 21(8), 1556-1561.
McLeod HL, Collie-Duguid ES, Vreken P, et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998;8(6):455–459.
Van Kuilenburg, A. B., Meinsma, R., Zoetekouw, L., & Van Gennip, A. H. (2002). Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. International journal of cancer, 101(3), 253–258. https://doi.org/10.1002/ijc.10599
Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., & Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical pharmacology and therapeutics, 103(2), 210–216. https://doi.org/10.1002/cpt.911
Amirfallah, A., Kocal, G. C., Unal, O. U., Ellidokuz, H., Oztop, I., & Basbinar, Y. (2018). DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients. Journal of personalized medicine, 8(4), 45. https://doi.org/10.3390/jpm8040045
Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol 2016;78(3):447–464.
Dyhl-Polk, A., Schou, M., Vistisen, K. K., Sillesen, A. S., Serup-Hansen, E., Faber, J., Klausen, T. W., Bojesen, S. E., Vaage-Nilsen, M., & Nielsen, D. L. (2021). Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study. The oncologist, 26(3), e403–e413. https://doi.org/10.1002/onco.13536
Shiga T, Hiraide M. Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. Curr Treat Options Oncol. 2020;21(4):27. Published 2020 Mar 19. doi:10.1007/s11864-020-0719-1
Kim, T. Y., Oh, D. Y., & Bang, Y. J. (2015). Capecitabine for the treatment of gastric cancer. Expert review of gastroenterology & hepatology, 9(12), 1471–1481. https://doi.org/10.1586/17474124.2015.1096774
Verma P. (2017). Capecitabine-induced acral and mucosal hyperpigmentation. Indian journal of dermatology, venereology and leprology, 83(5), 583. https://doi.org/10.4103/ijdvl.IJDVL_594_16
Yaghobi Joybari, A., Azadeh, P., Ghiasi, H. A., Amouzegar, A., Yaseri, M., Amini, A., ... & Mokhtari, M. (2019). Capecitabine induced fingerprint changes. Journal of Clinical Pharmacy and Therapeutics, 44(5), 780-787.
Lampropoulou, D. I., Laschos, K., Amylidi, A. L., Angelaki, A., Soupos, N., Boumpoucheropoulos, S., ... & Aravantinos, G. (2020). Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?. Journal of Oncology Pharmacy Practice, 26(3), 747-753.
Dyhl-Polk, A., Vaage-Nilsen, M., Schou, M., Vistisen, K. K., Lund, C. M., Kümler, T., ... & Nielsen, D. L. (2020). Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. Acta Oncologica, 59(4), 475-483.
Löwenberg, B. (2013). Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 121(1), 26-28.
Baker, W. J., Royer Jr, G. L., & Weiss, R. B. (1991). Cytarabine and neurologic toxicity. Journal of Clinical Oncology, 9(4), 679-693.
Sahasranaman, S., Howard, D., & Roy, S. (2008). Clinical pharmacology and pharmacogenetics of thiopurines. European journal of clinical pharmacology, 64(8), 753-767.
Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C. H., Yee, S. W., ... & Klein, T. E. (2011). Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clinical Pharmacology & Therapeutics, 89(3), 387-391.
Vora, A., Mitchell, C. D., Lennard, L., Eden, T. O., Kinsey, S. E., Lilleyman, J., & Richards, S. M. (2006). Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. The Lancet, 368(9544), 1339-1348.
Pettitt, A. R. (2003). Mechanism of action of purine analogues in chronic lymphocytic leukaemia. British journal of haematology, 121(5), 692-702.
Montillo, M., Ricci, F., & Tedeschi, A. (2006). Role of fludarabine in hematological malignancies. Expert review of anticancer therapy, 6(9), 1141-1161.
Robak, T., & Robak, P. (2012). Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Current pharmaceutical design, 18(23), 3373-3388.
Robak, P., & Robak, T. (2013). Older and new purine nucleoside analogs for patients with acute leukemias. Cancer treatment reviews, 39(8), 851-861.
Robak, T., Lech-Maranda, E., Korycka, A., & Robak, E. (2006). Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Current medicinal chemistry, 13(26), 3165-3189.
